|
 |
PanretinThis page contains recent news articles, when available, and an overview of Panretin but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Panretin (when available) Tretinoin, also known as all-trans-retinoic acid (ATRA), is a naturally occurring derivative of vitamin A (retinol). Retinoids such as tretinoin are important regulators of cell reproduction, proliferation, and differentiation and are used to treat acne and photodamaged skin and to manage keratinization disorders such as ichthyosis and keratosis follicularis. Tretinoin also represents the class of anticancer drugs called differentiating agents and is used in the treatment of acute promyelocytic leukemia (APL). For the the induction of remission in patients with acute promyelocytic leukemia (APL), French-American-British (FAB) classification M3 (including the M3 variant); For the topical treatment of acne vulgaris, flat warts and other skin conditions (psoriasis, ichthyosis congenita, icthyosis vulgaris, lamellar icthyosis, keratosis palmaris et plantaris, epidermolytic hyperkeratosis, senile comedones, senile keratosis, keratosis follicularis (Darier's disease), and basal cell carcinomas.); For palliative therapy to improve fine wrinkling, mottled hyperpigmentation, roughness associated with photodamage. Mechanism Of Action: Tretinoin binds to alpha, beta, and gamma retinoic acid receptors (RARs). RAR-alpha and RAR-beta have been associated with the development of acute promyelocytic leukemia and squamous cell cancers, respectively. RAR-gamma is associated with retinoid effects on mucocutaneous tissues and bone. Although the exact mechanism of action of tretinoin is unknown, current evidence suggests that the effectiveness of tretinoin in acne is due primarily to its ability to modify abnormal follicular keratinization. Comedones form in follicles with an excess of keratinized epithelial cells. Tretinoin promotes detachment of cornified cells and the enhanced shedding of corneocytes from the follicle. By increasing the mitotic activity of follicular epithelia, tretinoin also increases the turnover rate of thin, loosely-adherent corneocytes. Through these actions, the comedo contents are extruded and the formation of the microcomedo, the precursor lesion of acne vulgaris, is reduced. Tretinoin is not a cytolytic agent but instead induces cytodifferentiation and decreased proliferation of APL cells in culture and in vivo. When Tretinoin is given systemically to APL patients, tretinoin treatment produces an initial maturation of the primitive promyelocytes derived from the leukemic clone, followed by a repopulation of the bone marrow and peripheral blood by normal, polyclonal hematopoietic cells in patients achieving complete remission (CR). The exact mechanism of action of tretinoin in APL is unknown. News Articles on Tretinoin Eisai Pays $205 Million for Four Ligand Cancer Drugs - Sep 8, 2006 The agreement also covers rights to a gel version of Targretin, and a gel version of Panretin, used to treat skin lesions in patients with AIDS-related ... Bloomberg Ligand Completes Sale of Oncology Product Lines. - Oct 26, 2006 Targretin[R] (bexarotene) gel 1% and Panretin([R]) (alitretinoin) gel 0.1%. In addition, certain Ligand employees are being offered employment by Eisai. ... Free with registration - Business Wire - AccessMyLibrary.com Press Release: Stiefel Laboratories, Inc. Announces Duac Topical Gel ... - Sep 25, 2006 Article: International Panretin(TM) Topical Gel Trial ... ... Panretin(TM) (9-cis-retinoic acid) Topical Gel in patients with AIDS- related Kaposi ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Fougera First-To-Market With Metronidazole Topical Gel... - Jun 6, 2006 Article: International Panretin(TM) Topical Gel Trial ... ... Panretin(TM) (9-cis-retinoic acid) Topical Gel in patients with AIDS- related Kaposi ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: CLEAR SKIN IS THIS SEASON'S "MUST-HAVE" … - Aug 24, 2006 Article: International Panretin(TM) Topical Gel Trial ... ... Panretin(TM) (9-cis-retinoic acid) Topical Gel in patients with AIDS- related Kaposi ... Pay-Per-View - PR Newswire - HighBeam Research Article: Once-daily topical for psoriasis adds choice and convenience.... - Feb 1, 2006 Article: Ligand's Panretin Gel Granted European Marketing Authorization; ... ... Panretin gel is the first approved topical therapy in Europe for KS, ... Pay-Per-View - Skin & Allergy News - HighBeam Research Ligand Pharmaceuticals Inc. - Company Snapshot - AlacraStore.com - Nov 4, 2008 The major trademarks of the Group's are Ligand(R), ONTAK, Panretin, Targretin, ... The four oncology products marketed in the United States are Panretin (r) ... Pay-Per-View - co - Alacra Store Article: FDA approves topical combo of steroid, vitamin D for... - Feb 15, 2006 Article: Ligand's Panretin Gel Granted European Marketing Authorization; ... ... Panretin gel is the first approved topical therapy in Europe for KS, ... Pay-Per-View - Internal Medicine News - HighBeam Research Ligand Sells More Products: $205M For Cancer Portfolio - Sep 11, 2006 Targretin (bexarotene) gel and capsules, also for CTCL; and Panretin (alitretinoin) gel for Kaposi's sarcoma, an AIDS-related skin cancer. ... BioWorld Online - BioWorld Online Morning Updates for Monday, August 14,2006 - While One Company … - Aug 14, 2006 Ligand Pharmaceuticals also markets Panretin gel and Targretin capsules in Europe. The company also has various products in clinical development, ... Free with registration - M2 Presswire - AccessMyLibrary.com Press Release: Arpida Announces FDA Acceptance of the Iclaprim New … - May 16, 2008 Article: Ligand's Panretin(TM) Gel Demonstrates Positive Results in Second ... PR Newswire; December 10, 1997 ; 700+ words ... ... its North American Phase ... Pay-Per-View - PR Newswire - HighBeam Research Morning Updates for Friday, August 11,2006 - As One Company … - Aug 11, 2006 Ligand Pharmaceuticals also markets Panretin gel and Targretin capsules in Europe. The company also has various products in clinical development, ... Free with registration - M2 Presswire - AccessMyLibrary.com GIGM, TARO, VEGF, IGII, LGND, PPTI have been added to naked short … - Mar 21, 2006 Ligand Pharmaceuticals also markets Panretin gel and Targretin capsules in Europe. Further, the company has various products in clinical development, ... $4.95 - M2 Presswire - ECNext Press Release: Morning Updates for Friday, August 11,2006 - As One … - Aug 11, 2006 Ligand Pharmaceuticals also markets Panretin gel and Targretin capsules in Europe. The company also has various products in clinical development, ... Pay-Per-View - M2 Presswire - HighBeam Research Ligand to Restate Financials Back to 2002 - May 20, 2005 ...which is a cancer of the T-cells confined to the skin; Panretin gel, intended for AIDS patients who develop a skin cancer known as Kaposi's sarcoma, ... SanDiego.com Press Release: Serono Announces Results From Pivotal Phase III... - Aug 17, 2006 American pivotal Phase III trial of Panretin ... presented at the 12th International ... Patient responses to Panretin gel in Phase III investigations were ... Pay-Per-View - PR Newswire - HighBeam Research Eisai Taking Over Morphotek; $325M For Antibody Foothold - Mar 23, 2007 Targretin (bexarotene) gel and capsules, also for CTCL; and Panretin (alitretinoin) gel for Kaposi's sarcoma, an AIDS-related skin cancer. ... BioWorld Online - BioWorld Online Eisai buy cancer antibody specialists - Mar 23, 2007 ...cancer-related products from Ligand Pharmaceuticals last October: Ontak (denileukin), Panretin (alitretinoin) gel and Targretin (bexarotene) capsules ... LabTechnologist.com Press Release: Bellwether Report.com is Scouting Ligand … - Sep 11, 2006 Five of its products have received regulatory approval in the US or Europe: Panretin for AIDS-related Kaposi's sarcoma lesions; ONTAK for T-cell lymphoma; ... Pay-Per-View - M2 Presswire - HighBeam Research Vitamin A: Retinoids - Mar 29, 2008 Bexarotene (Targretin) treats cutaneous T-cell lymphoma, and alitretinoin (Panretin) treats Kaposi's sarcoma. Oral retinoids treat more severe conditions. ... Skincare News Magazine Japan's Eisai spreads its wings with $325 million acquisition of USA's... - Apr 2, 2007 It paid $205.0 million for Ligand's ONTAK (denileukin diftitox), Targretin (bexarotene) capsules and gel, and Panretin (alitretinoin) gel 0.1% (Marketletter ... Free with registration - Pharma Marketletter - AccessMyLibrary.com Stockioi watch list for: Tuesday, May 16, 2006 IPRE, XTHN, XOHO,... - May 17, 2006 The major trademarks, trade names and service marks of the Group include Ligand(R), ONTAK, Panretin, Targretin, and AVINZA. The four oncology products ... $4.95 - M2 Presswire - ECNext Article: StemCells Inc. surges on study - AP Worldstream | HighBeam … - Sep 20, 2005 Pharmaceuticals Incorporated (Nasdaq: LGND) today announced the ... results of its international Phase III pivotal trial for Panretin . ... Pay-Per-View - AP Worldstream - HighBeam Research BWR Begins Tracking Ligand Pharmaceuticals Inc. - Mar 19, 2007 It has received regulatory approval in the US or Europe for a handful of its products: Panretin for AIDS-related Kaposi's sarcoma lesions; ONTAK for T-cell ... Free with registration - M2 Presswire - AccessMyLibrary.com Ligand Pharmaceuticals Receives Leadership Award from Frost & … - Jan 3, 2005 Targretin(R) gel and Panretin(R) gel. Ligand's fifth and newest product, AVINZA(R), is a treatment for chronic, moderate-to-severe pain. ... $4.95 - Business Wire - ECNext Press Release: Vernalis plc Announces Proposed Acquisition of Cita … - Nov 18, 2005 PR Newswire; March 26, 1998 ; 700+ words ... ... the final results of its international Phase III pivotal trial for Panretin(TM) gel ... the North American ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: 3SBio Inc. Files for SFDA Approval of NuLeusin. - PR … - Nov 10, 2008 PR Newswire; March 26, 1998 ; 700+ words ... ... the final results of its international Phase III pivotal trial for Panretin(TM) gel ... the North American ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: InterMune Announces Presentations at the 56th Annual … - Nov 8, 2005 PR Newswire; March 26, 1998 ; 700+ words ... ... the final results of its international Phase III pivotal trial for Panretin(TM) gel ... the North American ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Gene Signal Enters Phase III Clinical Tests for the … - Nov 10, 2008 PR Newswire; March 26, 1998 ; 700+ words ... ... the final results of its international Phase III pivotal trial for Panretin(TM) gel ... the North American ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: GSAT, ITMN, MBTF, PRWT, WFII, WRSP Have Also Been … - May 29, 2007 Pharmaceuticals Incorporated (Nasdaq: LGND) today announced the ... results of its international Phase III pivotal trial for Panretin . ... Pay-Per-View - M2 Presswire - HighBeam Research Article: John Higgins.(Newsmakers)(Ligand Pharmaceuticals Inc.... - Feb 19, 2007 Ligand Pharmaceuticals Inc.'s drug to treat AIDS patients has been endorsed by an FDA panel. The committee has recommended approval of Panretin ... ... Pay-Per-View - Chain Drug Review - HighBeam Research Press Release: InterMune Announces Second Quarter Financial Results. ... - Jul 28, 2005 PR Newswire; March 26, 1998 ; 700+ words ... ... the final results of its international Phase III pivotal trial for Panretin(TM) gel ... the North American ... Pay-Per-View - PR Newswire - HighBeam Research Article: Guidelines endorse earlier treatment of HIV.(News)(Human … - Sep 1, 2008 NDA) which Ligand submitted to the U.S. Food & Drug Administration on May 26, 1998. Patient responses to Panretin gel in ... ... Pay-Per-View - Internal Medicine News - HighBeam Research Competitors by Product Report - Jun 21, 2008 ...(Monoclonal Antibody); MORAb-009 (Monoclonal Antibody); Ontak (Denileukin Diftitox); Panretin Capsules (Alitretinoin); Targretin Capsules (Bexarotene) ... $75.00 - Revere Reports - Revere Merger and Acquisition Scenario - Apr 28, 2007 Pharmaceuticals: ONTAK (denileukin diftitox), Targretin (bexarotene) capsules, Targretin (bexarotene) gel 1% and Panretin (alitretinoin) gel 0.1%. ... $250.00 - Revere Reports - Revere Press Release: DRAXIS Provides Update on FIBRIMAGE(R) … - May 5, 2005 PR Newswire; March 26, 1998 ; 700+ words ... ... the final results of its international Phase III pivotal trial for Panretin(TM) gel ... the North American ... Pay-Per-View - PR Newswire - HighBeam Research Eisai gains recognition as 'human health care company'. - Apr 28, 2008 Eisai obtained exclusive rights for Ontak, Targretin capsules, Targretin gel and Panretin from Ligand. Eisai also enjoys success by following what the ... $9.94 - Chain Drug Review - Alacra Store Merger and Acquisition Scenario - May 19, 2007 Pharmaceuticals: ONTAK (denileukin diftitox), Targretin (bexarotene) capsules, Targretin (bexarotene) gel 1% and Panretin (alitretinoin) gel 0.1%. ... $250.00 - Revere Reports - Revere Press Release: Roche Announces Successful Completion of Four Pivotal ... - Dec 16, 2005 PR Newswire; March 26, 1998 ; 700+ words ... ... the final results of its international Phase III pivotal trial for Panretin(TM) gel ... the North American ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Retigabine Significantly Reduces the Number of... - Dec 6, 2008 PR Newswire; March 26, 1998 ; 700+ words ... ... the final results of its international Phase III pivotal trial for Panretin(TM) gel ... the North American ... Pay-Per-View - PR Newswire - HighBeam Research Avinza acquisition.(RXs)(Brief article) | Article from Chain Drug... - Mar 19, 2007 Ligand Pharmaceuticals Inc.'s drug to treat AIDS patients has been endorsed by an FDA panel. The committee has recommended approval of Panretin ... ... Pay-Per-View - Chain Drug Review - HighBeam Research Competitors by Product Report - Jun 21, 2008 ...(Monoclonal Antibody); MORAb-009 (Monoclonal Antibody); Ontak (Denileukin Diftitox); Panretin Capsules (Alitretinoin); Targretin Capsules (Bexarotene) ... $75.00 - Revere Reports - Revere Press Release: Vanda Pharmaceuticals Reports Second Quarter 2007 … - Aug 2, 2007 PR Newswire; March 26, 1998 ; 700+ words ... ... the final results of its international Phase III pivotal trial for Panretin(TM) gel ... the North American ... Pay-Per-View - PR Newswire - HighBeam Research Merger and Acquisition Scenario - Jan 27, 2007 Pharmaceuticals: ONTAK (denileukin diftitox), Targretin (bexarotene) capsules, Targretin (bexarotene) gel 1% and Panretin (alitretinoin) gel 0.1%. ... $250.00 - Revere Reports - Revere Press Release: Spectral's EAA(TM) to be used in Phase III study for a... - Apr 9, 2008 PR Newswire; March 26, 1998 ; 700+ words ... ... the final results of its international Phase III pivotal trial for Panretin(TM) gel ... the North American ... Pay-Per-View - PR Newswire - HighBeam Research Merger and Acquisition Scenario - May 19, 2007 Pharmaceuticals: ONTAK (denileukin diftitox), Targretin (bexarotene) capsules, Targretin (bexarotene) gel 1% and Panretin (alitretinoin) gel 0.1%. ... $250.00 - Revere Reports - Revere Press Release: Arthrosurface HemiCAP(R) Focal Knee Resurfacing … - Sep 5, 2008 PR Newswire; March 26, 1998 ; 700+ words ... ... the final results of its international Phase III pivotal trial for Panretin(TM) gel ... the North American ... Pay-Per-View - PR Newswire - HighBeam Research Merger and Acquisition Scenario - Jun 16, 2007 Pharmaceuticals: ONTAK (denileukin diftitox), Targretin (bexarotene) capsules, Targretin (bexarotene) gel 1% and Panretin (alitretinoin) gel 0.1%. ... $250.00 - Revere Reports - Revere Competitors by Product Report - Mar 29, 2008 MGi Pharma ZYC300 (DNA Based Immunostimulant); Ontak (Denileukin Diftitox); Panretin Capsules (Alitretinoin); Targretin Capsules (Bexarotene) ... $75.00 - Revere Reports - Revere A Ligand Is Reborn - Jun 16, 2006 T-cell lymphoma; and Panretin gel, for the treatment of Kaposi's sarcoma in AIDS patients. It's also expanding indications for its marketed products. ... Smartmoney.com Eisai to Acquire Global Rights to Four Oncology-Related Products from... - Sep 8, 2006 ...(Nasdaq: LGND) for exclusive global rights for their four oncology-related products, ONTAK, Targretin capsules, Targretin gel 1% and Panretin gel 0.1%. ... StreetInsider.com - StreetInsider.com (subscription) How to take Acitretin from Consumer Reports Health. - Jan 8, 2006 ...tell your doctor and pharmacist if you are allergic to acitretin, other retinoids such as adapalene (Differen), alitretinoin (Panretin), ... consumerreports.org Local Therapy - Mar 14, 2006 Alitretinoin, a substance related to vitamin A, is available as a gel (Panretin ® ) that can be used to treat KS skin lesions. ... ACS News Center Eisai Acquires Four Oncology-Related Products from Ligand. - Sep 8, 2006 ONTAK (denileukin diftitox), Targretin (bexarotene) capsules, Targretin (bexarotene) gel 1% and Panretin (alitretinoin) gel 0.1%. ... Free with registration - JCNN News Summaries - AccessMyLibrary.com Ligand Leans Toward Selling. - Jan 10, 2006 San Diego-based drug developer Ligand markets three skin disease treatments-Panretin gel and Targretin capsules and gel-as well as the ONTAK fusion protein ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Press Release: Organon's Sugammadex Demonstrated a 9-12 Times … - Jun 11, 2007 PR Newswire; March 26, 1998 ; 700+ words ... ... the final results of its international Phase III pivotal trial for Panretin(TM) gel ... the North American ... Pay-Per-View - PR Newswire - HighBeam Research Competitors by Product Report - Jun 21, 2008 MGi Pharma ZYC300 (DNA Based Immunostimulant); Ontak (Denileukin Diftitox); Panretin Capsules (Alitretinoin); Targretin Capsules (Bexarotene) ... $75.00 - Revere - Alacra Store Press Release: MIGENIX Reports Third Quarter Fiscal Year 2008 … - Mar 13, 2008 PR Newswire; March 26, 1998 ; 700+ words ... ... the final results of its international Phase III pivotal trial for Panretin(TM) gel ... the North American ... Pay-Per-View - PR Newswire - HighBeam Research Merger and Acquisition Scenario - Apr 7, 2007 Pharmaceuticals: ONTAK (denileukin diftitox), Targretin (bexarotene) capsules, Targretin (bexarotene) gel 1% and Panretin (alitretinoin) gel 0.1%. ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Nov 25, 2006 Pharmaceuticals: ONTAK (denileukin diftitox), Targretin (bexarotene) capsules, Targretin (bexarotene) gel 1% and Panretin (alitretinoin) gel 0.1%. ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Dec 16, 2006 Pharmaceuticals: ONTAK (denileukin diftitox), Targretin (bexarotene) capsules, Targretin (bexarotene) gel 1% and Panretin (alitretinoin) gel 0.1%. ... $250.00 - Revere Reports - Revere Competitors by Product Report - Jun 21, 2008 MGi Pharma ZYC300 (DNA Based Immunostimulant); Ontak (Denileukin Diftitox); Panretin Capsules (Alitretinoin); Targretin Capsules (Bexarotene) ... $75.00 - Revere - Alacra Store Untitled - Jan 31, 2008 Panretin....................................................................... .............77. Targretin. ... $2,020.00 - ESPICOM HEALTHCARE INTELLIGENCE - Alacra Store Press Release: Arpida Receives Green Light From US FDA for Phase II … - Jan 15, 2008 PR Newswire; March 26, 1998 ; 700+ words ... ... final results of its international Phase III pivotal trial for Panretin(TM . ... Pay-Per-View - PR Newswire - HighBeam Research Eisai; Recent developments announced by Eisai - Dec 5, 2006 ...global rights for Ontak (denileukin diftitox), Targretin (bexarotene) capsules, Targretin (bexarotene) gel 1% and Panretin (alitretinoin) gel 0.1%. ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Press Release: Stem Cell Company t2cure Appoints Dr Rueck Head of … - Feb 25, 2008 PR Newswire; March 26, 1998 ; 700+ words ... ... the final results of its international Phase III pivotal trial for Panretin(TM) gel ... the North American ... Pay-Per-View - PR Newswire - HighBeam Research Eisai buys 4 cancer drugs from Ligand Pharma. - Sep 18, 2006 Panretin gel (alitretinoine) is used against the cutaneous lesions associated with Kaposi's sarcoma (which affects Aids patients). ... Pay-Per-View - Chimie Pharma Hebdo - Factiva, from Dow Jones Competitors by Product Report - Mar 15, 2008 MGi Pharma ZYC300 (DNA Based Immunostimulant); Ontak (Denileukin Diftitox); Panretin Capsules (Alitretinoin); Targretin Capsules (Bexarotene) ... $75.00 - Revere Reports - Revere Press Release: Eisai Acquires Four Oncology-Related Products From … - Sep 7, 2006 Targretin(R) (bexarotene) gel 1% and Panretin(R) (alitretinoin) gel 0.1%. In addition, certain Ligand personnel will be offered employment by Eisai Inc. ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Axcan announces outcome of ITAX International Phase... - Feb 22, 2006 PR Newswire; March 26, 1998 ; 700+ words ... ... the final results of its international Phase III pivotal trial for Panretin ... both the North American and ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Lilly Reports Second-Quarter EPS of $.76. - PR... - Jul 21, 2006 PR Newswire; March 26, 1998 ; 700+ words ... ... the final results of its international Phase III pivotal trial for Panretin(TM) gel ... the North American ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Neurorecovery, Inc. Updates Clinical Development … - Dec 19, 2006 PR Newswire; March 26, 1998 ; 700+ words ... ... the final results of its international Phase III pivotal trial for Panretin(TM) gel ... the North American ... Pay-Per-View - PR Newswire - HighBeam Research Merger and Acquisition Scenario - Dec 16, 2006 Pharmaceuticals: ONTAK (denileukin diftitox), Targretin (bexarotene) capsules, Targretin (bexarotene) gel 1% and Panretin (alitretinoin) gel 0.1%. ... $250.00 - Revere Reports - Revere Press Release: New Trial Results Support Best-in-Class Heart Failure ... - Sep 6, 2006 PR Newswire; March 26, 1998 ; 700+ words ... ... the final results of its international Phase III pivotal trial for Panretin(TM) gel ... the North American ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Vanda Pharmaceuticals Reports Third Quarter 2006 … - Nov 2, 2006 The international pivotal Phase III trial was stopped early in August of ... of the North American pivotal Phase III trial of Panretin gel in KS which were ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Pharmion Corporation Announces Q1 2006 Financial … - Apr 27, 2006 PR Newswire; March 26, 1998 ; 700+ words ... ... the final results of its international Phase III pivotal trial for Panretin(TM) gel ... the North American ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Delcath Systems Announces a New Site for the Phase III... - Aug 18, 2006 PR Newswire; March 26, 1998 ; 700+ words ... ... the final results of its international Phase III pivotal trial for Panretin(TM) gel ... the North American ... Pay-Per-View - PR Newswire - HighBeam Research Eisai Acquires Four Oncology-Related Products From Ligand. - Sep 7, 2006 Targretin(R) (bexarotene) gel 1% and Panretin(R) (alitretinoin) gel 0.1%. In addition, certain Ligand personnel will be offered employment by Eisai Inc. ... $4.95 - PR Newswire - ECNext Press Release: IVI Awarded Bahamas Assignments. - PR Newswire | … - Oct 4, 2006 PR Newswire; March 26, 1998 ; 700+ words ... ... the final results of its international Phase III pivotal trial for Panretin(TM) gel ... the North American ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Eisai Announces Completion of Acquisition of Four … - Oct 26, 2006 ...rights to ONTAK(R) (denileukin diftitox), Targretin(R) (bexarotene) capsules, Targretin(R) (bexarotene) gel 1% and Panretin(R) (alitretinoin) gel 0.1%. ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Bellwether Report.com is Following Ligand … - Sep 8, 2006 Five of its products have received regulatory approval in the US or Europe: Panretin for AIDS-related Kaposi's sarcoma lesions; ONTAK for T-cell lymphoma; ... Pay-Per-View - M2 Presswire - HighBeam Research Press Release: In Addition to Oncology Products, the Special … - May 25, 2006 Matthew T. Witte, formerly ... and Panretin(R) gel comprise the oncology products unit. "These business units should ... ... Pay-Per-View - M2 Presswire - HighBeam Research Dal donepezil agli oncologici - Sep 12, 2006 ...nel trattamento delle lesioni cutanee causate dal linfoma a cellule T. e alitretinoina (Panretin) gel, contro il sarcoma di Kaposi associato all'Aids. ... Pharma Marketing Quand le HHV8 rencontre le VIH - Oct 30, 2008 Ce type de traitement inclut l'application locale d'un gel d'alitrétinoïne (acide rétinoïque, Panretin®). La lésion peut aussi être traitée localement par ... Act Up-Paris Article: AP Top News at 5:34 am EST - AP Online | HighBeam Research -... - Dec 13, 2005 Article: Ligand Submits First NDA For Panretin(R) Gel For Kaposi's Sarcoma ... PR Newswire; May 28, 1998 ; 700+ words ... ... Incorporated (Nasdaq: LGND) ... Pay-Per-View - AP Online - HighBeam Research Article: AP Top News at 5:36 am EST - AP Online | HighBeam Research -... - Dec 13, 2005 Article: Ligand Submits First NDA For Panretin(R) Gel For Kaposi's Sarcoma ... PR Newswire; May 28, 1998 ; 700+ words ... ... Incorporated (Nasdaq: LGND) ... Pay-Per-View - AP Online - HighBeam Research Article: Surprise Sheds New Light On Diabetes. - Hartford Courant ( … - Jun 13, 2006 Article: Ligand Submits First NDA For Panretin(R) Gel For Kaposi's Sarcoma ... PR Newswire; May 28, 1998 ; 700+ words ... ... Incorporated (Nasdaq: LGND) ... Pay-Per-View - Hartford Courant - HighBeam Research Article: Never too late to change your mind. - Australasian Business ... - Sep 26, 2005 Article: Ligand Submits First NDA For Panretin(R) Gel For Kaposi's Sarcoma ... PR Newswire; May 28, 1998 ; 700+ words ... ... Incorporated (Nasdaq: LGND) ... Pay-Per-View - Australasian Business Intelligence - HighBeam Research Article: AP Top News at 5:37 am EST - AP Online | HighBeam Research -... - Dec 13, 2005 Article: Ligand Submits First NDA For Panretin(R) Gel For Kaposi's Sarcoma ... PR Newswire; May 28, 1998 ; 700+ words ... ... Incorporated (Nasdaq: LGND) ... Pay-Per-View - AP Online - HighBeam Research Press Release: TopCoder Software(TM) Delivers Web-Based Interactive … - Jan 25, 2005 Article: Ligand Submits First NDA For Panretin(R) Gel For Kaposi's Sarcoma ... PR Newswire; May 28, 1998 ; 700+ words ... ... Incorporated (Nasdaq: LGND) ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Neurome, Inc. Announces Publication of New Research … - Jul 19, 2005 Article: Ligand Submits First NDA For Panretin(R) Gel For Kaposi's Sarcoma ... PR Newswire; May 28, 1998 ; 700+ words ... ... 1988 agreement with The Salk ... Pay-Per-View - PR Newswire - HighBeam Research Article: AP Top News at 5:41 am EST - AP Online | HighBeam Research -... - Dec 13, 2005 Article: Ligand Submits First NDA For Panretin(R) Gel For Kaposi's Sarcoma ... PR Newswire; May 28, 1998 ; 700+ words ... ... Incorporated (Nasdaq: LGND) ... Pay-Per-View - AP Online - HighBeam Research Article: Ligand nets $2m milestone.(Ligand Pharmaceuticals Inc... - Feb 27, 2006 Article: Ligand Pharmaceuticals' Panretin Gel for ... Business Wire; July 13, 1998 ; 700+ words ... ... 000 and 50000 patients in the United States and ... Pay-Per-View - San Diego Business Journal - HighBeam Research Article: Genes tell plants when to wake up and stretch. - Australasian... - Sep 23, 2008 Article: Ligand Submits First NDA For Panretin(R) Gel For Kaposi's Sarcoma ... PR Newswire; May 28, 1998 ; 700+ words ... ... Incorporated (Nasdaq: LGND) ... Pay-Per-View - Australasian Business Intelligence - HighBeam Research Article: NeuroVigil Wins First Prize at UCSD $50K Innovation Competiti... - Jul 6, 2008 Article: Ligand Submits First NDA For Panretin(R) Gel For Kaposi's Sarcoma ... PR Newswire; May 28, 1998 ; 700+ words ... ... Incorporated (Nasdaq: LGND) ... Pay-Per-View - Wireless News - HighBeam Research Article: Salk Institute.(GOVERNMENT AND NONPROFIT)(appointment of … - Sep 10, 2007 Article: Ligand Submits First NDA For Panretin(R) Gel For Kaposi's Sarcoma ... PR Newswire; May 28, 1998 ; 700+ words ... ... Incorporated (Nasdaq: LGND) ... Pay-Per-View - San Diego Business Journal - HighBeam Research Article: The Mingei International Museum will honor Architect David … - Apr 30, 2007 Article: Ligand Submits First NDA For Panretin(R) Gel For Kaposi's Sarcoma ... PR Newswire; May 28, 1998 ; 700+ words ... ... Incorporated (Nasdaq: LGND) ... Pay-Per-View - San Diego Business Journal - HighBeam Research Article: Gateway Founder, Chairman Waitt to Retire - AP Online | … - May 19, 2005 Article: Ligand Submits First NDA For Panretin(R) Gel For Kaposi's Sarcoma ... PR Newswire; May 28, 1998 ; 700+ words ... ... Incorporated (Nasdaq: LGND) ... Pay-Per-View - AP Online - HighBeam Research Press Release: Salk Institute Lights Up in Pink and Blue. - PR... - Sep 13, 2005 Article: Ligand Submits First NDA For Panretin(R) Gel For Kaposi's Sarcoma ... PR Newswire; May 28, 1998 ; 700+ words ... ... Nasdaq: LGND) and The Salk ... Pay-Per-View - PR Newswire - HighBeam Research Brand Names/Synonyms: Panretin is also known by the following brand names and/or synonymsAberel; Accutane; Airol; Aknefug; Aknoten; All Trans Retinoic Acid; All Trans-Retinoic Acid; Amnesteem; Avita; Beta-Retinoic Acid; Claravis; Dermairol; Eudyna; Isotretinoin; Lsotretinoin; Panretin; Renova; Retin-A; Retin-a Micro; Retinoate; Retinoic Acid; Retinoic Acid, All Trans Isomer; Retionic Acid; Retisol-A; Solage; Sotret; Stieva-A; Stieva-a Forte; Trans-Retinoic Acid; Tretin M; Tretinoin; Tri-Luma; Vesanoid; Vitamin a Acid; Vitinoin; β-Retinoic Acid Drug Category: Panretin is categorized under the following by the FDA: Keratolytic Agents; Antineoplastic Agents; Cell Stimulants and Proliferants (84:16.00); ATC:D10AD01; ATC:D10AD04; ATC:D10BA01; ATC:L01XX14; ATC:L01XX22 Dosage Forms: CAPSULE; CREAM; GEL; LIQUID Absorption: 1-31% (topical); Interactions: [an error occurred while processing this directive] Chemical IUPAC Name: 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)-nona-2,4,6,8-tetraenoic acid |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |